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Background. Both peroxisome activator proteins (PPARs) and fetuin-A play a role in lipid and glucose metabolism. Aims. We
investigated whether PPAR𝛼 intron 7 G2468/C and PPAR𝛾2 Pro12Ala and PPAR𝛾 exon 6 C161T polymorphisms are associated
with serum fetuin-A concentrations. Patients and Methods. The PPAR𝛼 intron 7 G/C polymorphism was studied in cohort 1 (79
reference individuals, 165 postinfarction patients). The two PPAR𝛾 polymorphisms were investigated in cohort 2 (162 reference
individuals, 165 postinfarction patients). Fetuin-A levels and PPAR polymorphisms were determined by radial immunodiffusion
and polymerase chain reaction-restriction fragment length polymorphism techniques.Results.TheC allele variant of PPAR𝛼 intron
7 G2467C was associated with higher fetuin-A levels (𝑝 = 0.018). Postinfarction status (𝑝 = 0.001), PPAR𝛼 intron 7 GG/GC/CC
genotypes (𝑝 = 0.032), and the C allele (𝑝 = 0.021) were the strongest determinants of fetuin-A concentration in a multiple
regression model. Higher fetuin-A levels were associated with the Pro variant of PPAR𝛾2 (𝑝 = 0.047). Postinfarction status (𝑝 =
0.041) and BMI (𝑝 < 0.001) but not PPAR𝛾2 Pro were the strongest determinants of fetuin-A concentrations. PPAR𝛾 exon 6 C161T
genotypes were not associated with fetuin-A levels. Conclusions. Fetuin-A was determined mainly by the PPAR𝛼 intron 7C allele
and postinfarction status in cohort 1 and the BMI and postinfarction in cohort 2. The PPAR𝛼 intron 7C and PPAR𝛾2 Pro variants
are associated with fetuin-A levels.
1. Introduction
Human fetuin-A is a multifunctional hepatic glycoprotein
that has been involved in the development of obesity [1–
3], insulin resistance [4], metabolic syndrome [1, 5], type 2
diabetes [6–8], adipocyte dysfunction [9], and fatty liver [4].
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily of
ligand-activated transcription factors. The PPAR subgroups
PPAR𝛼, PPAR𝛽/𝛿, and PPAR𝛾 (𝛾1 and 𝛾2) play an important
role in the pathogenesis of these processes, which has been
extensively reviewed [10–12].
There are several observations suggesting a relationship
between serum fetuin-A levels and activities of different
PPARs. For example, the direct inhibitory effect of pioglita-
zone on hepatic fetuin-A expression has been observed in rats
[13] and in humans [14]; the formerwas reversed byGW9602,
direct PPAR𝛾 inhibitor.
Polymorphisms of PPAR𝛾 and PPAR𝛼 have also been
described and found to be associated with disorders of
hyperlipidemia, glucose homeostasis, and diabetes. Thus the
C allele of the PPAR𝛼 intron 7 polymorphism was found to
be more frequent in patients with myocardial infarction and
dyslipidemia [15]. The T allele of the PPAR𝛾 exon 6 C161T
polymorphism was supposed to have protective role against
coronary artery disease in Chinese population [16], whereas
others found that this allele was associated with an increased
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risk for coronary heart disease [12]. The association between
polymorphic variants of PPAR and serum fetuin-A levels,
however, has not been investigated yet.
In our study, we aimed to investigate whether polymor-
phisms of PPAR𝛾 (PPAR𝛾2 Pro12Ala and exon 6 C161T) and
PPAR𝛼 (intron 7 G2467C) are associated with or may affect
serum fetuin-A levels in two cohorts.
2. Patients and Methods
Three-hundred and forty-two patients were originally
involved in this study. Exclusion criteria were as follows:
clinical or laboratory signs of acute vascular disease
(myocardial infarction, stroke), acute infection, malignant
tumor, hepatic disease, renal failure, immune suppression,
severe medical or surgical conditions, and trauma. Finally,
we had 327 patients (cohort 2) who had all comparable
data (including successful genotyping for both PPAR𝛾
polymorphisms). We were able to perform successful PPAR𝛼
genotyping in a smaller number of patients (cohort 1,
𝑛 = 244). The genotyping success rate was greater than 99%
in both cohorts. The genotypes were in the Hardy-Weinberg
equilibrium.
PPAR𝛼 polymorphism was studied in cohort 1. This
cohort comprised 244 individuals (120 men and 124 women,
age: 60.1 ± 11.2 years, mean ± SD). Cohort 1 consisted of
79 reference individuals (15 men, 64 women, age: 61.0 ± 9.4
years) and 165 patients surviving myocardial infarction (105
men, 60 women, age: 59.6 ± 12.2 years).
PPAR𝛾 polymorphisms were studied in cohort 2. This
cohort consisted of 327 individuals (161 men, 166 women,
age: 57.9 ± 13.0 years). This cohort consisted of 162 reference
subjects (61 men, 101 women, age: 56.1 ± 13.8 years) and the
same 165 postinfarction patients as in cohort 1 (105 men, 60
women, age: 59.6 ± 12.2 years).
Postinfarction patients had a history of STEMI myocar-
dial infarction (6–24 months prior to the start of the study).
Diabetes was diagnosed based on fasting plasma glucose >
7.0mmol/l or the 2-hr OGTT > 11.1mmol/l. Patients with
diabetes were treated with diet, metformin, and bedtime
insulin.
All persons gave their informed consent prior to their
inclusion in the study. The study was approved by the
local Ethics Committee of the Ka´rolyi Sa´ndor Municipality
Hospital.
2.1. Determination of PPAR Polymorphic Variants. The deter-
mination of the PPAR𝛾 and PPAR𝛼 variants was performed
by PCR-RFLP technique.
The PPAR𝛼G2467C intron 7 polymorphism (rs 4253778)
was studied by PCR-RFLP technique, using a 5󸀠 forward
primer of ACA ATC ACT CCT TAA ATA TGG TGG
and a 3󸀠 reverse primer of AAG TAG GGA CAG ACA
GGA CCA GTA. The PCR product was digested with Taq1
(New England Biolabs, Boston, MA, USA) resulting in one
fragment of 266 bp of the carriers of the wild-type allele and
two fragments of 216 and 50 bp in the carriers of the mutant
allele (thermocycles 94∘C 15min, 30 × 94∘C 30 sec, 50∘C
20 sec, and 72∘C 30 sec) [17].
For PPAR𝛾Pro12Ala (rs 1801282) polymorphism, we used
a 5󸀠 forward primer of GCC AAT TCA AGC CCA GTC and
a mutagenic 3󸀠 reverse primer of GAT ATG TTT GCA GAC
AGT GTA TCA GTG AAG GAA TCG CTT TCC G. The
PCR product was digested with Bst U1 enzyme (NewEngland
Biolabs, Boston, MA, USA) resulting in one fragment of
270 bp in the carriers of wild-type and two fragments of 227
and 43 bp in carriers of mutant allele (thermocycles 95∘C
15min, 35 × 94∘C 30 sec, 65∘C 45 sec, and 72∘C 1min) [18].
The exon 6 polymorphism C161T of PPAR𝛾 (rs 3856806)
was investigated by PCR-RFLP technique using a 5󸀠 forward
primer of CAA GAC AAC CTG CTA CAA GC and a 3󸀠
reverse primer of TCC TTG TAG ATC TCC TGC AG. The
PCR product was digested with Pml1 enzyme (New England
Biolabs, Boston, MA, USA) resulting in two fragments of
120 and 80 bp in carriers of the wild-type allele and only
one fragment of 200 bp in the carriers of the mutant allele
(thermocycles 94∘C 15min, 30× 94∘C 30 sec, 56∘C 30 sec, and
72∘C 30 sec) [19].
2.2. Determination of Serum Fetuin-A Concentration. Serum
fetuin-A concentrations were determined by radial immun-
odiffusion using the commercially available product (anti-
fetuin-A, IgG fraction, Incstar, cat. number 81931, 13.7mg/ml,
in a final concentration of 84 𝜇l/11.5ml gel), as previously
described [20].
2.3. Determination of Insulin Resistance Parameters. Plasma
glucose and insulin were determined by the routine HK-
G6P-DH and ELCIAmethods, respectively.TheHomeostasis
Model Assessment-Insulin Resistance (HOMA-IR) model
was calculated according to Matthews et al. [21].
2.4. Statistical Analysis. Statistical analysis was carried out
using the SPSS v.21 statistical software (SPSS Inc., Chicago,
IL, USA). Nonparametric methods, including the Bonferroni
(Dunn) post hoc test, were used. 𝑝 values < 0.05 were
considered as significant.
3. Results
3.1. Subject Characteristics. The characteristics of the study
participants are shown in Table 1.
Sixty-five per cent of the postinfarction patients received
statins and 70% of them aspirin. Serum fetuin-A concentra-
tions did not differ statistically between patients treated and
not treated with these two medications (687 ± 122 versus 636
± 81mg/l, 𝑝 = 0.204 for statins and 665 ± 0.120 versus 672 ±
124mg/l, 𝑝 = 0.795 for aspirin, resp.).
3.2. PPAR𝛼 Intron 7 G/C, PPAR𝛾2 Pro12Ala, and PPAR𝛾
Exon 6 C161TAllele Distribution in Postinfarction Patients and
Reference Individuals. Thedistribution of PPAR𝛾 andPPAR𝛼
alleles is shown in Table 2. PPAR𝛾 Pro12Ala and PPAR𝛼
intron 7 G/C alleles did not differ significantly between
postinfarction patients and reference subjects. Postinfarction
patients, however, had a significantly higher T allele fre-
quency of the PPAR𝛾 C161T compared to reference subjects.
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Table 1: Subject characteristics.
Cohort 1
(𝑛 = 244)
Cohort 2
(𝑛 = 327)
Reference individuals
(𝑛 = 79)
Postinfarction patients
(𝑛 = 165)
Reference individuals
(𝑛 = 162)
Postinfarction patients
(𝑛 = 165)
Gender (male/female) 15/64 105/60 61/101 105/60
Age (years, mean ± SD) 61.0 ± 9.4 59.6 ± 12.2 56.1 ± 13.8 59.6 ± 12.2
BMI (kg/m2) 24.1 ± 1.6 28.1 ± 4.2∗∗ 27.4 ± 0.4 28.1 ± 4.2∗
Obesity (no/yes) 68/11 46/119∗∗ 78/84 46/119∗∗
Diabetes status (no/yes) 79/0 112/53∗∗ 139/23 112/53∗∗
HOMA-IR 1.0 ± 0.2 6.2 ± 4.6∗∗ 1.5 ± 1.5 6.1 ± 4.6∗∗
∗𝑝 < 0.01 and ∗∗𝑝 < 0.001, compared to reference individuals; BMI: body mass index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance;
Mann–Whitney test.
Table 2:ThePPAR𝛼 intron 7G/C, PPAR𝛾2 Pro12Ala, andPPAR𝛾 exon 6C161T allele distribution amongpostinfarction patients and reference
individuals.
Allelic frequency 𝜒2 RR(95% CI)
OR
(95% CI) 𝑝
PPAR𝛼 intron 7 G/C (rs4253778)
G P: 0.8273R: 0.8165 0.0861
1.013
(0.9271–1.107)
1.077
(0.6571–1.764) 0.769
C P: 0.1727R: 0.1835
PPAR𝛾2 Pro12Ala (rs1801282)
Pro12 P: 0.8618R: 0.8789 0.4279
0.9804
(0.9241–1.040)
0.8583
(0.5428–1.3570) 0.513
Ala12 P: 0.1382R: 0.1211
PPAR𝛾 exon 6 C161T (rs3856806)
C P: 0.8735R: 0.9459 10.25
0.9235
(0.8799–0.9693)
0.3953
(0.2204–0.7091) 0.001
T P: 0.1265R: 0.0541
P: postinfarction patients; R: reference subjects; 𝑝: 𝜒2 test.
3.3. Analysis of Association between PPAR𝛼 Intron 7 G2467C
Variants and Serum Fetuin-A Concentrations. Serum fetuin-
A levels of individuals with the CC genotype were higher
than those of GG genotype (Table 3). In the dominant
model (C versus non-C nucleotide), individuals with the
minor variant C allele had significantly higher serum fetuin-
A concentrations than those with the non-C. In a recessive
model (G versus non-G nucleotide), there was no difference
between the two variants (651 ± 107mg/l, 𝑛 = 238 versus 662
± 171mg/l, 𝑛 = 6, 𝑝 = 0.702).
Except for age, serum fetuin-A concentrations showed
significant correlations with parameters listed in Table 4.
Serum fetuin-A levels associatedweakly but significantly with
PPAR𝛼 intron 7 GG/GC/CC genotypes and the C allele but
not with the G allele. During partial correlation analysis,
however, the correlation between fetuin-A concentrations
and PPAR𝛼 intron 7 GG/GC/CC genotype lost significance
when corrected for BMI (𝑟 = 0.100, 𝑝 = 0.125), diabetes
status (𝑟 = 0.108, 𝑝 = 0.092), HOMA-IR (𝑟 = 0.116,
𝑝 = 0.072), and postinfarction status (𝑟 = 0.122, 𝑝 =
0.058). Correlation between fetuin-A levels and the PPAR𝛼
intron 7C allele also became insignificant when corrected for
BMI (𝑟 = 0.107, 𝑝 = 0.095), diabetes status (𝑟 = 0.115,
𝑝 = 0.072), and HOMA-IR (𝑟 = 0.123, 𝑝 = 0.056) but
remained significant after correction for postinfarction status
(𝑟 = 0.131, 𝑝 = 0.041).
The results of the univariate linear regression analy-
sis between independent variables (predictors) and serum
fetuin-A concentration (dependent variable) are shown in
Table 5. Serum fetuin-A levels showed weak but statistically
significant data with all investigated potential predictors,
including PPAR𝛼 intron 7 G/C genotypes and the C allele but
not with age. Thus age was excluded from further analysis.
Next we investigated whether PPAR𝛼 intron 7 G/C
genotype and the C allele may determine serum fetuin-
A concentration in a multiple regression model (Table 6).
In the model containing all independent parameters, we
investigated the PPAR𝛼 intron 7 GG/GC/CC genotype and
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Table 3: Serum fetuin-A concentrations in individuals with different PPAR𝛼 intron 7 G2467C SNP polymorphisms and alleles.
(a) PPAR𝛼 intron 7 G2467C polymorphisms
GG GC CC
𝑝
Fetuin-A mg/l 𝑛 Fetuin-A mg/l 𝑛 Fetuin-A mg/l 𝑛
641 ± 150 164 671 ± 110 74 662 ± 170 6 0.040#
(b) PPAR𝛼 intron 7 G2467C alleles
C allele non-C
𝑝
Fetuin-A mg/l 𝑛 Fetuin-A mg/l 𝑛
670 ± 114 80 641 ± 105 164 0.018§
#Kruskal-Wallis test; §Mann–Whitney test.
Table 4: Correlation between serum fetuin-A and investigated
parameters (𝑛 = 244).
Parameter Correlation coefficient 𝑝
BMI 0.167 0.009
Diabetes status (no/yes) 0.133 0.038
HOMA-IR 0.205 0.001
Age −0.109 0.188
Gender −0.168 0.017
Postinfarction status (no/yes) 0.277 <0.001
PPAR𝛼 GG/GC/CC 0.144 0.025
PPAR𝛼 C allele 0.151 0.018
PPAR𝛼 G allele 0.025 0.700
BMI: body mass index; HOMA-IR: Homeostasis Model Assessment-Insulin
Resistance; Spearman correlation.
Table 5: Univariate regression analysis between serum fetuin-A
concentrations and metabolic parameters (𝑛 = 244).
Predictor Standardized 𝛽 𝑝
BMI 0.146 0.023
Diabetes status (no/yes) 0.136 0.034
HOMA-IR 0.163 0.011
Postinfarction status (no/yes) 0.212 0.001
Age −0.137 0.098
Gender −0.149 0.027
PPAR𝛼 GG/GC/CC 0.131 0.042
PPAR𝛼 C allele 0.140 0.029
BMI: body mass index; HOMA-IR: Homeostasis Model Assessment-Insulin
Resistance.
the C allele were the only statistically significant predictors
of serum fetuin-A levels. In a backward stepwise regres-
sion model, the postinfarction status, the PPAR𝛼 intron 7
GG/GC/CC genotypes, and the C allele proved to be the
strongest determinants of fetuin-A concentration.
3.4. Analysis of Association between PPAR𝛾2 Pro12Ala Vari-
ants and Serum Fetuin-A Concentrations. Patients with
Pro/Pro and Pro/Ala genotype had significantly higher serum
fetuin-A concentrations than those with the Ala/Ala geno-
type (Pro/Pro: 681 ± 131mg/l, 𝑛 = 247, Pro/Ala: 706 ±
131mg/l, 𝑛 = 75, and Ala/Ala: 565 ± 116mg/l, 𝑛 = 5,
𝑝 = 0.043, Kruskal-Wallis test). In the recessive model (Pro
versus non-Pro), the fetuin-A level associated with the allele
determining Pro exceeded that of the non-Pro variant (687 ±
131mg/l, 𝑛 = 322 versus 565 ± 116mg/l, 𝑛 = 5, 𝑝 = 0.047,
Mann–Whitney test). Fetuin-A concentrations did not differ
in the recessive model (Ala versus non-Ala) (698 ± 143mg/l,
𝑛 = 80 versus 681 ± 131mg/l, 𝑛 = 247, 𝑝 = 0.287).
Serum fetuin-A concentration was significantly associ-
ated with BMI, HOMA-IR, gender, and the Pro allele but not
with the diabetes and postinfarction status, PPAR𝛾 Pro/Pro,
Pro/Ala, and Ala/Ala genotypes or the Ala allele (Table 7).
Thus these two latter parameters were left out from further
analysis.The correlation between fetuin-A concentration and
the Pro allele was lost following correction for BMI and
gender but not with HOMA-IR (Table 8).
Univariate regression analysis showed that serum fetuin-
A (dependent variable) weakly but significantly correlated
with BMI and the PPAR𝛾 Pro allele (independent variable,
Table 9). This latter independent variable lost its predictor
role when BMI was included in the regression model.
In the multiple backward stepwise regression model,
postinfarction status (𝛽 = 0.111, 𝑝 = 0.041) and BMI (𝛽 =
0.426, 𝑝 < 0.001) proved to be the strongest determinants of
fetuin-A concentrations.
3.5. Analysis of Association between PPAR𝛾 Exon 6 C161T
Variants and Serum Fetuin-A Concentrations. We found no
significant differences among serum fetuin-A concentrations
of individuals with different PPAR𝛾 exon 6 C161T genotypes,
nor between the C and non-C or T and non-T groups
(Table 10). Fetuin-A levels did not correlate with the PPAR𝛾
C161T genotypes, C, and T alleles, either (data not shown).
There were 3 minor variant homozygotes (TT) in the
postinfarction but none in the reference group. Thus the
genotype distribution of postinfarction patients markedly
differed from that of reference individuals (CC/CT/TT:
130/37/3 versus 140/17/0, 𝑝 = 0.006). The T allele was
significantly more frequent among postinfarction patients
compared to reference group (40/170 = 23.5% versus 17/157 =
10.8%, 𝑝 = 0.002). Accordingly, postinfarction patients with
the CC genotype had lower fetuin-A levels than reference
subjects (668 ± 113mg/l, 𝑛 = 130 versus 710 ± 146mg/l,
𝑛 = 140, 𝑝 = 0.037).
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Table 6: Multiple regression analysis of PPAR𝛼 intron 7 G/C genotypes and C allele and serum fetuin-A concentration (𝑛 = 244).
Predictor PPAR𝛼 intron 7 GG/GC/GG PPAR𝛼 intron 7 C allele
Standardized 𝛽 𝑝 Standardized 𝛽 𝑝
All predictors included
BMI 0.027 0.708 −0.024 0.743
Diabetes status (no/yes) 0.054 0.474 0.045 0.551
HOMA-IR 0.037 0.651 0.035 0.666
Postinfarction status (no/yes) 0.130 0.127 0.132 0.121
Gender −0.079 0.260 −0.083 0.242
PPAR𝛼 intron 7 genetics# 0.134 0.036 0.144 0.024
Model fit: 𝑝 = 0.006 Model fit: 𝑝 = 0.005
Stepwise backward regression
Postinfarction status (no/yes) 0.214 0.001 0.215 0.001
PPAR𝛼 intron 7 genetics# 0.135 0.032 0.144 0.021
Model fit: 𝑝 < 0.001 Model fit: 𝑝 < 0.001
#Regression parameters of the PPAR𝛼 intron 7 GG/GC/GG genotypes are indicated in the second and the third and those of the PPAR𝛼 intron 7 C allele in
the fourth and fifth columns of the table, respectively; BMI: body mass index; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance.
Table 7: Correlation between serum fetuin-A and investigated
parameters (𝑛 = 327).
Parameter Correlation coefficient 𝑝
BMI 0.426 <0.001
Diabetes status (no/yes) 0.102 0.064
HOMA-IR 0.129 0.027
Gender −0.178 0.008
Postinfarction status
(no/yes) 0.098 0.078
PPAR𝛾 Pro/Pro, Pro/Ala,
and Ala/Ala 0.050 0.365
PPAR𝛾 Pro allele 0.130 0.018
PPAR𝛾 Ala allele 0.052 0.349
BMI: body mass index HOMA-IR: Homeostasis Model Assessment-Insulin
Resistance; Spearman correlation.
Table 8: Partial correlation between serum fetuin-A concentrations
and PPAR𝛾 Pro allele (𝑛 = 327).
Corrected for Correlation coefficient 𝑝
Uncorrected 0.130 0.018
BMI 0.069 0.215
HOMA-IR 0.129 0.027
Gender 0.129 0.055
4. Discussion
In our study, we investigated whether PPAR𝛼 intron 7 G/C,
PPAR𝛾2 Pro12Ala, and PPAR𝛾 C161T variants are associated
with serum fetuin-A concentration. Since subjects in our
groups had several parameters that are known to affect fetuin-
A levels such as age, gender, BMI, parameters of insulin
resistance (diabetes status, HOMA-IR), and postinfarction
status [22], we chose regression model to estimate the impact
of these variables.
Table 9: Univariate regression analysis between serum fetuin-A
concentrations and predictor parameters (𝑛 = 327).
Predictor Standardized 𝛽 𝑝
BMI 0.520 <0.001
Diabetes status (no/yes) 0.065 0.239
HOMA-IR 0.059 0.291
Postinfarction status (no/yes) 0.137 0.013
PPAR𝛾 Pro allele 0.127 0.022
PPAR𝛾 Pro allele
+ BMI
0.059
0.512
0.215
<0.001
BMI: body mass index; HOMA-IR: Homeostasis Model Assessment-Insulin
Resistance.
PPAR𝛼 has been termed as a lipid sensor and is involved
in microsomal 𝜔-oxidation and mitochondrial and peroxi-
somal 𝛽-oxidation resulting in energy burning and reduced
fat storage [11]. The minor variant of the PPAR𝛼 intron 7C
has been considered to have a decreased activity compared
to G, the major variant. The C haplotype promotes the early
development of type 2 diabetes [17] and is more frequent
among postinfarction patients [12, 15]. Doney et al. have
found that the risk of myocardial infarction is higher in the
presence of the C allele [23]. We also have found that the
C allele is associated with higher fetuin-A levels and the
multiple regression revealed that fetuin-A levels are strongly
determined by the postinfarction status and remarkably by
the PPAR𝛼 intron 7 G/C polymorphism, as well. Although
the C allele was not more frequent among our postinfarction
patients, the higher fetuin-A concentration may also have
deleterious effects in them. Elevated fetuin-A concentration is
amarker of fatty liver, characterized by decreased𝛽-oxidation
of fatty acids [4].
Fetuin-A is synthesized almost exclusively by the hepa-
tocytes in adults [24] and the PPAR𝛼 is mainly expressed in
the liver, as well. Fetuin-A is known as an endogenous ligand
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Table 10: Serum fetuin-A concentrations in individuals with different PPAR𝛾 exon 6 C161T polymorphisms and alleles (𝑛 = 327).
(a) PPAR exon 6 C161T polymorphisms
CC CT TT
𝑝
Fetuin-A mg/l 𝑛 Fetuin-A mg/l 𝑛 Fetuin-A mg/l 𝑛
690 ± 133 270 661 ± 125 54 641 ± 104 3 0.340#
(b) PPAR𝛾 exon 6 C161T Ala Allele
Fetuin-A mg/l 𝑛 Fetuin-A mg/l 𝑛 𝑝
C non-C
685 ± 132 324 641 ± 104 3 0.674§
T non-T
659 ± 123 57 690 ± 133 270 0.138§
#Kruskal-Wallis test; §Mann–Whitney test.
that binds to free fatty acids and functions as an endoge-
nous ligand for the Toll-like receptor TLR-4 thereby linking
metabolic diseases (hyperlipidemia, insulin resistance) and
subclinical inflammation [25]. This “missing link” character
of fetuin-A has been further supported by the clinical studies
of Stefan and Ha¨ring [26]. These findings are in line with
our observation that postinfarction status, an endpoint of
subclinical inflammation, and PPAR𝛼 intron 7C allele were
the strongest determinants of fetuin-A in our subjects.
Compared to Ala metabolically disadvantageous char-
acteristics are attributed to the Pro variant of PPAR𝛾2
Pro12Ala [27]. Indeed, we found only the Pro allele among
individuals with BMI over 25 kg/m2 and only lean (BMI
≤ 25 kg/m2) subjects had the Ala/Ala homozygous variant.
Nevertheless, even among individuals with the Ala variant,
obesity was associated with higher fetuin-A levels compared
to lean ones. Patients with diabetes had higher fetuin-A
levels, the difference being significant in Pro/Pro major allele
homozygotes (704 ± 124mg/l, 𝑛 = 64 versus 673 ± 132mg/l,
𝑛 = 183, 𝑝 = 0.020). Since fetuin-A is known to be the
natural inhibitor of the insulin receptor tyrosine kinase, the
Pro allele may convey increased insulin resistance. Indeed,
we found minor variant Ala to be more frequent among
nondiabetics (68/251 = 27.1%) compared to diabetics (12/76
= 15.8%, 𝑝 = 0.044).This finding is in accordance with that of
Vergotine, who observed that the Pro allele increases insulin
resistance, alongwith IRS1Gly972 [28]. Conversely, theminor
allele Ala seemed to be protective in Iranian and Chinese
populations [29, 30]. In our model, however, the relationship
of fetuin-A levels with BMI and postinfarction status was
much stronger than the one with insulin resistance (diabetes
status or HOMA). The Pro allele was associated with higher
fetuin-A in the nondiabetic group, as well, which is reflected
by the weak correlation with diabetes status and HOMA-IR.
Given the property of fetuin-A to increase insulin resistance,
its weak association with the Pro allele can contribute to the
deleterious effects of this allele.
Analysis of the effect of the PPAR𝛾 C161T variants on
serum fetuin-A concentrations yielded the least consistent
results. We had 3 minor homozygotes (TT) among the
postinfarction patients but not among the reference subjects.
This finding is in accord with the observation of Qian et al.,
who found that coronary heart disease was not associated
with the T-carrier state but these individuals had higher risk
for acute coronary heart syndrome [12]. Wu et al. found mild
protective effect of the T allele only in the Chinese but not in
other populations [16]. We found no marked associations of
C161T genotypes and alleles neither in postinfarction patients
nor in the reference group, and not during the analysis of
nonobese, nondiabetic individuals. This suggests that the
C161T has the weakest association with fetuin-A levels out
of the three PPAR polymorphisms we studied. Since PPAR𝛾
is expressed mainly in the fat tissue, its association with the
levels of the liver secretory protein fetuin-A cannot be as close
as that of PPAR𝛼.
Although not yet entirely clarified, several observations
suggest the molecular basis of the association between
PPAR variants and fetuin-A synthesis. The PPAR𝛼 agonist
fibrates decrease fetuin-A expression in obese patients with
or without type 2 diabetes mellitus [31]. The PPAR𝛾 agonist
pioglitazone strongly inhibits fetuin-A expression [14]. The
upregulation of both PPAR𝛼 and PPAR𝛾 results in the
downregulation of fetuin-A and NF𝜅B and upregulation of
the AMPK kinase activities. Palmitate, the oxidation of which
is highly induced by PPAR𝛼, has been shown to stimulate
NF𝜅B binding to the fetuin-A promoter [9]. Thus a less
functional variant of PPAR𝛼 could finally result in enhanced
fetuin-A expression.
Our study has its limitations. First, the sample size is not
big enough to allow for analysis of a comparable number of
minor variants. Second, our cohorts were not controlled for
environmental factors and prescribedmedication and dietary
saturated and polyunsaturated fat as it has been suggested
[32].
5. Conclusion
In summary, our results indicate a relatively close relationship
between PPAR𝛼 intron 7 G/C and PPAR𝛾2 Pro12Ala variants
and serum fetuin-A concentrations reflecting higher levels
in the presence of the C allele of the former and the Pro
allele of the latter one. It is very likely that these associations
PPAR Research 7
are obscured by obesity and/or diabetes. Larger scale studies
are needed to further determine the biological and clinical
significance of the PPAR polymorphisms on fetuin-A levels.
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